Roche Digs In To Early Breast Cancer With New Perjeta Approvals
• By Emily Hayes
Roche's HER2 franchise got a boost with new early breast cancer approvals for Perjeta. Above, immunohistochemistry for HER2 shows positive cell membrane staining in infiltrating ductal carcinoma.
Keep up with the top pharma business news of the week. On the go.
